Last reviewed · How we verify

VADADUSTAT — Competitive Intelligence Brief

VADADUSTAT (VADADUSTAT) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitor [EPC].

marketed Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitor [EPC] Small molecule Live · refreshed every 30 min

Target snapshot

VADADUSTAT (VADADUSTAT).

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
VADADUSTAT TARGET VADADUSTAT marketed Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitor [EPC] 2023-01-01
Jesduvroq DAPRODUSTAT GSK marketed Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitor [EPC] Egl nine homolog 1 2023-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitor [EPC] class)

  1. · 1 drug in this class
  2. GSK · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). VADADUSTAT — Competitive Intelligence Brief. https://druglandscape.com/ci/vadadustat. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: